Company profile: Aderis Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical products for the diagnosis and treatment of cardio-renal and cardiovascular diseases, including adenosine agonists and antagonists; focused on discovery, development and commercialization.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aderis Pharmaceuticals
BioDelivery Sciences International
HQ: United States
Website
- Description: Provider of pharmaceutical solutions focused on pain management and addiction medicine, leveraging proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize new applications of proven therapies independently or through partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioDelivery Sciences International company profile →
PAQ Therapeutics
HQ: United States
Website
- Description: Provider of an autophagy-based drug discovery platform using ATTEC autophagosome-tethering compounds to degrade disease-causing proteins, lipids, and other substrates. Collaborates with Insilico Medicine to develop small molecule therapies via AI-driven drug discovery, with initial work in a genetic neurodegenerative disorder and plans to expand to diseases lacking treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PAQ Therapeutics company profile →
SyntheticMR
HQ: Sweden
Website
- Description: Provider of innovative magnetic resonance imaging software that supports shorter exam times and delivers more information to clinicians. Products include SyMRI NEURO for quantitative MRI with contrast images, tissue segmentation, and volumetric measurements in a single scan; SyMRI MSK for musculoskeletal imaging with quantitative maps and contrast images; and MAGiC, a GE Healthcare version offering customizable MRI imaging solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SyntheticMR company profile →
Alliance
HQ: United States
Website
- Description: Provider of in-home neurodiagnostic testing services, including video EEG testing and remote EEG monitoring, as well as cardiac monitoring solutions such as mobile cardiac telemetry, extended Holter testing, and event monitoring, plus cloud-based EEG software for secure access to EEG data and synchronized review of EEG and video recordings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alliance company profile →
Protagenic Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions developing naturally occurring human brain hormones to treat anxiety- and depression-based mood disorders. Offers PT00114, a synthetic analog of the neuropeptide TCAP that regulates stress response for depression, PTSD, anxiety, and addiction, and the TCAP R&D platform to address neuropsychiatric and neurodegenerative diseases at the cellular level in the brain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protagenic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aderis Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aderis Pharmaceuticals
2.2 - Growth funds investing in similar companies to Aderis Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aderis Pharmaceuticals
4.2 - Public trading comparable groups for Aderis Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →